Neurosteroid enantiomer
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mild Traumatic Brain Injury, Concussion
Conditions
Mild Traumatic Brain Injury, Concussion
Trial Timeline
Jun 1, 2025 → Mar 31, 2026
NCT ID
NCT06870240About Neurosteroid enantiomer
Neurosteroid enantiomer is a phase 2 stage product being developed by Oragenics for Mild Traumatic Brain Injury, Concussion. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06870240. Target conditions include Mild Traumatic Brain Injury, Concussion.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06870240 | Phase 2 | Recruiting |
Competing Products
20 competing products in Mild Traumatic Brain Injury, Concussion